P
ProNovo Therapeutics develops novel, precision therapeutics targeting unmet medical needs in neuropsychiatric disorders like Major Depressive Disorder and Schizophrenia. The company integrates genetic susceptibility and prognostic biomarkers into its de-risked medicine strategy to create high-impact treatments. Its pipeline includes first-in-class and best-in-class opportunities for depression and schizophrenia, respectively.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- ProNovo Therapeutics develops novel, precision therapeutics targeting unmet medical needs in neuropsychiatric disorders like Major Depressive Disorder and Schizophrenia. The company integrates genetic susceptibility and prognostic biomarkers into its de-risked medicine strategy to create high-impact treatments. Its pipeline includes first-in-class and best-in-class opportunities for depression and schizophrenia, respectively.